Eflornithine is an ornithine decarboxylase inhibitor used to prevent relapse of high-risk neuroblastoma in pediatric and adult patients. Eflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis.
- Mechanism
- Curator reviewed · 1 reference
Eflornithine is an irreversible inhibitor of the enzyme ornithine decarboxylase (ODC), the first and rate-limiting enzyme in the biosynthesis of polyamines and a transcriptional target of MYCN. Polyamines are involved in the differentiation and proliferation of mammalian cells and are important for neoplastic transformation.
- Primary indication
- Eflornithine is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.Curator reviewed · 3 structured indications
- Formula / weight
- C6H12F2N2O2 · 182.171 g/mol (avg)
- First approval
- Canada, 2015 · United States, 2000 · European Union, 2020
- Also known as
- alpha-difluoromethylornithine · DFMO · Difluoromethylornithine
- Code names
- BRN 2250529 · HSDB 7923 · MDL-71782 · RFI 7178 · RMI-71782
- Brand names
Resolves to
VLCYCQAOQCDTCN-UHFFFAOYSA-NSMILESNCCCC(N)(C(F)F)C(O)=OWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Eflornithine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account